{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["cannabigerol", "cannabigerolic acid", "dog", "hemp", "pharmacokinetics"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35246858", "DateCompleted": {"Year": "2022", "Month": "12", "Day": "23"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "23"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "03", "Day": "04"}], "Language": ["eng"], "ELocationID": ["10.1111/jvp.13048"], "Journal": {"ISSN": "1365-2885", "JournalIssue": {"Volume": "45", "Issue": "3", "PubDate": {"Year": "2022", "Month": "May"}}, "Title": "Journal of veterinary pharmacology and therapeutics", "ISOAbbreviation": "J Vet Pharmacol Ther"}, "ArticleTitle": "Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation.", "Pagination": {"StartPage": "245", "EndPage": "254", "MedlinePgn": "245-254"}, "Abstract": {"AbstractText": ["The use of cannabinoids in veterinary medicine has been increasing exponentially recently and there is little information regarding the pharmacokinetics of cannabinoids except for cannabidiol (CBD) and tetrahydrocannabinol (THC), with even more sparse information related to their native acid forms found in cannabis. Cannabigerol (CBG) is the precursor molecule to cannabinoid formation in the cannabis plant which may have medicinal properties as well, yet there are no publications related to CBG or the native cannabigerolic acid (CBGA) in companion animal species. The aim of this study was to investigate similar dosing of CBG and CBGA from hemp plants that have been used for cannabidiol pharmacokinetic studies. Administration in the fed and fasted state was performed to better understand absorption and retention of these unique hemp-derived cannabinoids in dogs. Results suggest that when providing a hemp-derived CBG/CBGA formulation in equal quantities, CBGA is absorbed approximately 40-fold better than CBG regardless of being given to fed or fasted dogs. After twice daily dosing for two weeks at 2\u00a0mg/kg in the fasted and then fed state, no differences in the mean serum CBG (5\u00a0ng/ml) or CBGA (250\u00a0ng/ml) serum concentrations were observed between states. Importantly, physical examination, complete blood counts, and serum chemistry evaluations over the two weeks suggest no adverse events during this short-term dosing trial."], "CopyrightInformation": "\u00a9 2022 John Wiley & Sons Ltd."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hometown Veterinary Hospital and River Canine Rehabilitation, Springfield, Missouri, USA."}], "LastName": "Amstutz", "ForeName": "Kara", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Medicine, Cornell University College of Veterinary Medicine, Ithaca, New York, USA."}], "LastName": "Schwark", "ForeName": "Wayne S", "Initials": "WS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toxicology Research Laboratory, Department of Pharmacology, University of Illinois Medical College, Chicago, Illinois, USA."}], "LastName": "Zakharov", "ForeName": "Alexander", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toxicology Research Laboratory, Department of Pharmacology, University of Illinois Medical College, Chicago, Illinois, USA."}], "LastName": "Gomez", "ForeName": "Beatriz", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toxicology Research Laboratory, Department of Pharmacology, University of Illinois Medical College, Chicago, Illinois, USA."}], "LastName": "Lyubimov", "ForeName": "Alex", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA."}], "LastName": "Ellis", "ForeName": "Karolynn", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA."}], "LastName": "Venator", "ForeName": "Kurt P", "Initials": "KP"}, {"Identifier": ["0000-0003-4397-6081"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA."}], "LastName": "Wakshlag", "ForeName": "Joseph J", "Initials": "JJ"}], "GrantList": [{"Agency": "Ellevet Sciences", "Country": ""}], "PublicationTypeList": ["Clinical Trial, Veterinary", "Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Vet Pharmacol Ther", "NlmUniqueID": "7910920", "ISSNLinking": "0140-7783"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Benzoates"}, {"RegistryNumber": "19GBJ60SN5", "NameOfSubstance": "Cannabidiol"}, {"RegistryNumber": "J1K406072N", "NameOfSubstance": "cannabigerol"}, {"RegistryNumber": "25555-57-1", "NameOfSubstance": "cannabigerolic acid"}, {"RegistryNumber": "0", "NameOfSubstance": "Cannabinoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Dogs"}, {"QualifierName": [], "DescriptorName": "Administration, Oral"}, {"QualifierName": [], "DescriptorName": "Benzoates"}, {"QualifierName": [], "DescriptorName": "Cannabidiol"}, {"QualifierName": ["chemistry"], "DescriptorName": "Cannabinoids"}, {"QualifierName": ["chemistry"], "DescriptorName": "Cannabis"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plant Extracts"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Anderson, L. L., Etchart, M. G., Bahceci, D., Golembiewski, T. A., & Arnold, J. C. (2021). Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations. Scientific Reports, 11, 14948. https://doi.org/10.1038/s41598-021-94212-6"}, {"Citation": "Anderson, L. L., Heblinski, M., Absalom, N. L., Hawkins, N. A., Bowen, M. T., Benson, M. J., Zhang, F., Bahceci, D., Doohan, P. T., Chebib, M., McGregor, I. S., Kearney, J. A., & Arnold, J. C. (2021). Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British Journal of Pharmacology, 178, 4826-4841. https://doi.org/10.1111/bph.15661"}, {"Citation": "Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., & Rahman, M. M. (2008). Antibacterial cannabinoids from Cannabis sativa: a structure\u2212 activity study. Journal of Natural Products, 71, 1427-1430. https://doi.org/10.1021/np8002673"}, {"Citation": "Bartner, L., McGrath, S., Rao, S., Hyatt, L., & Wittenburg, L. (2018). Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Canadian Journal of Veterinary Research, 83, 178-183."}, {"Citation": "Beardsley, P., Scimeca, J., & Martin, B. (1987). Studies on the agonistic activity of \u03949-11-tetrahydrocannabinol in mice, dogs, and rhesus monkeys and its interactions with \u03949-tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics, 241(2), 521-526."}, {"Citation": "Birnbaum, A. K., Karanam, A., Marino, S. E., Barkley, C. M., Remmel, R. P., Roslawski, M., Gramling-Aden, M., & Leppik, I. E. (2019). Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia, 60, 1586-1592. https://doi.org/10.1111/epi.16093"}, {"Citation": "Bornheim, L. M., & Correia, M. A. (1989). Effect of cannabidiol on cytochrome P-450 isozymes. Biochemical Pharmacology, 38, 2789-2794. https://doi.org/10.1016/0006-2952(89)90432-2"}, {"Citation": "Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maeillo, F., Coppola, D., Orlando, P., Battista, G., Pagano, E., Marzo, V., & Izzo, A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85, 1306-1316. https://doi.org/10.1016/j.bcp.2013.01.017"}, {"Citation": "Borrelli, F., Pagano, E., Romano, B., Panzera, S., Maiello, F., Coppola, D., De Petrocelis, L., Buono, L., Orlando, P., & Izzo, A. (2014). Colon carcinogenesis is inhibited by the TRPM8 antagonist, cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis, 35, 2787-2797. https://doi.org/10.1093/carcin/bgu205"}, {"Citation": "Brutlag, A., & Hommerding, H. (2018). Toxicology of marijuana, synthetic cannabinoids, and cannabidiol in dogs and cats. Veterinary Clinics in Small Animal Practice, 48, 1087-1102. https://doi.org/10.1016/j.cvsm.2018.07.008"}, {"Citation": "Cascio, M., Gauson, L., Stevenson, L., Ross, R., & Pertwee, R. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent \u03b12-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology, 159, 129-141. https://doi.org/10.1111/j.1476-5381.2009.00515.x"}, {"Citation": "Colasanti, B. A. (1990). Comparison of the ocular and central effects of \u03949-tetrahydrocannabinol and cannabigerol. Journal of Ocular Pharmacology and Therapeutics, 6, 259-269. https://doi.org/10.1016/0014-4835(84)90013-7"}, {"Citation": "Dai, Y. I. (2016). TRPs and pain. Seminars in Immunopathology, 38, 277-291. https://doi.org/10.1007/s00281-015-0526-0"}, {"Citation": "De Caro, C., Cristiano, C., Avagliano, C., Bertamino, A., Ostacolo, C., Campiglia, P., Gomez-Monterrey, I., La Rana, G., Gualillo, O., Calignano, A., & Russo, R. (2019). Characterization of new TRPM8 modulators in pain perception. International Journal of Molecular Science, 20, 5544. https://doi.org/10.3390/ijms20225544"}, {"Citation": "De Petrocellis, L., Ligresti, A., Schiano Moriello, A., Iappelli, M., Verde, R., Stott, C. G., Cristino, L., Orlando, P., & Di Marzo, V. (2013). Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. British Journal of Pharmacology, 168, 79-102. https://doi.org/10.1111/j.1476-5381.2012.02027.x"}, {"Citation": "De Petrocellis, L., Orlando, P., Moriello, A. S., Aviello, G., Stott, C., Izzo, A. A., & Di Marzo, V. (2012). Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiologica, 204, 255-266. https://doi.org/10.1111/j.1748-1716.2011.02338.x"}, {"Citation": "Deabold, K. A., Schwark, W. S., Wolf, L., & Wakshlag, J. J. (2019). Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. Animals (Basel), 9(10), 832. https://doi.org/10.3390/ani9100832"}, {"Citation": "Deiana, S. C. (2017). Potential medical uses of cannabigerol: a brief overview handbook of cannabis and related pathologies biology. Pharmacology, Diagnosis, and Treatment, 99, 958-967."}, {"Citation": "Eichler, M., Spinedi, L., Unfer-Grauwiler, S., Bodmer, M., Surber, C., Luedi, M., & Drewe, J. (2012). Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Medica, 78, 686-691. https://doi.org/10.1055/s-0031-1298334"}, {"Citation": "Eisohly, H. N., Turner, C. E., Clark, A. M., & Eisohly, M. A. (1982). Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. Journal of Pharmacological Sciences, 71, 1319-1323. https://doi.org/10.1002/jps.2600711204"}, {"Citation": "Farha, M. A., El-Halfawy, O. M., Gale, R. T., MacNair, C. R., Carfrae, L. A., Zhang, X., & Brown, E. D. (2020). Uncovering the hidden antibiotic potential of cannabis. ACS Infectious Diseases, 6, 338-346. https://doi.org/10.1021/acsinfecdis.9b00419"}, {"Citation": "Fellermeier, M., & Zenk, M. (1998). Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol. FEBS Letters, 427, 283-285. https://doi.org/10.1016/s0014-5793(98)00450-5"}, {"Citation": "Gamble, L. J., Boesch, J., Frye, C., Schwark, W., Mann, S., Wolfe, L., Brown, H., Berthelsen, E., & Wakshlag, J. J. (2018). Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Frontiers in Veterinary Science, 23, 1-9. https://doi.org/10.3389/fvets.2018.00165"}, {"Citation": "Gaoni, Y., & Mechoulam, R. (1964). The structure and function of Cannabigerol, a new hashish constituent. Proceedings of the Chemistry Society; B, 1, 82."}, {"Citation": "Granholm, M., McKusick, B. C., Westerholm, F. C., & Aspegr\u00e9n, J. C. (2007). Evaluation of the clinical efficacy and safety of intramuscular and intravenous doses of dexmedetomidine and medetomidine in dogs and their reversal with atipamezole. The Veterinary Record, 160, 891-897. https://doi.org/10.1136/vr.160.26.891"}, {"Citation": "Hlo\u017eek, T., Uttl, L., Kade\u0159\u00e1bek, L., Bal\u00edkov\u00e1, M., Lhotkov\u00e1, E., Horsley, R. R., Nov\u00e1kov\u00e1, P., \u0160\u00edchov\u00e1, K., \u0160tefkov\u00e1, K., Tyl\u0161, F., Kucha\u0159, M., & P\u00e1len\u00ed\u010dek, T. (2017). Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Journal of the European College of Neuropsychopharmacology, 27, 1223-1237. https://doi.org/10.1016/j.euroneuro.2017.10.037"}, {"Citation": "Khan, Z. P., Ferguson, C. N., & Jones, R. M. (1999). Alpha-2 and imidazoline receptor agonists. Their Pharmacology and Therapeutic Role. Anaesthesia, 55, 146-165. https://doi.org/10.1046/j.1365-2044.1999.00659.x"}, {"Citation": "\u0141ebkowska-Wieruszewska, B., Stefanelli, F., Chericoni, S., Owen, H., Poapolathep, A., Lisowski, A., & Giorgi, M. (2019). Pharmacokinetics of Bedrocan\u00ae, a cannabis oil extract, in fasting and fed dogs: An explorative study. Research in Veterinary Science, 123, 26-28. https://doi.org/10.1016/j.rvsc.2018.12.003"}, {"Citation": "McGrath, S., Bartner, L. R., Rao, S., Kogan, L. R., & Hellyer, P. W. (2018). A report of adverse effects associated with the administration of cannabidiol in healthy dogs. Journal of the American Holistic Veterinary Medical Association, 52, 34-38."}, {"Citation": "McGrath, S., Bartner, L. R., Rao, S., Packer, R. A., & Gustafson, D. L. (2019). Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association, 254, 1301-1308. https://doi.org/10.2460/javma.254.11.1301"}, {"Citation": "Mukerji, G., Yiangou, Y., Corcoran, S. L., Selmer, I. S., Smith, G. D., Benham, C. D., Bountra, C., Agarwal, S. K., & Anand, P. (2006). Cool and menthol receptor TRPM8 in human urinary bladder disorders and clinical correlations. BMC Urology, 6(6), 6. https://doi.org/10.1186/1471-2490-6-6"}, {"Citation": "Nachnani, R., Raup-Konsavage, W., & Vrana, K. (2021). The pharmacological case for cannabigerol. Journal of Pharmacology and Experimental Therapeutics, 376, 204-212. https://doi.org/10.1124/jpet.120.000340"}, {"Citation": "Perlin, E., Smith, C. G., Nichols, A. I., Almirez, R., Flora, K. P., Cradock, J. C., & Peck, C. C. (1985). Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. Journal of Pharmaceutical Sciences, 74, 171-174. https://doi.org/10.1002/jps.2600740213"}, {"Citation": "Russo, E. (2011). Taming THC: potential cannabis synergy and phytocannabinoids-terpenoid entourage effects. British Journal of Pharmacology, 163, 1344-1364. https://doi.org/10.1111/j.1476-5381.2011.01238.x"}, {"Citation": "Silver, R. (2019). The endocannabinoid system of animals. Animals, 9, 686-694. https://doi.org/10.3390/ani9090686"}, {"Citation": "Turner., S. (2017). Molecular Pharmacology of Phytocannabinoids. In A. D. Kinghorn, H. Falk, S. Gibbons, & J. Kobayashi (Eds.), Progress in the Chemistry of Organic Natural Products. Ch:103 Phytocannabinoids, Unraveling the Complex Chemistry and Pharmacology of Cannabis sativa. (p. 87)."}, {"Citation": "Wakshlag, J. J., Cital, S., Eaton, S. J., Prussin, R., & Hudalla, C. (2020). Cannabinoid, terpene, and heavy metal analysis of 29 over-the-counter commercial veterinary hemp supplements. Veterinary Medicine (Auckl), 11, 45-55. https://doi.org/10.2147/VMRR.S248712"}, {"Citation": "Wakshlag, J. J., Schwark, W. S., Deabold, K. A., Talsma, B. N., Cital, S., Lyubimov, A., Iqbal, A., & Zakharov, A. (2020). Pharmacokinetics of cannabidiol, cannabidiolic acid, \u03949-tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract. Frontiers in Veterinary Science, 7, 505. https://doi.org/10.3389/fvets.2020.00505"}, {"Citation": "Wang, M., Wang, Y. H., Avula, B., Radwan, M., Wanas, A., van Antwerp, J., Parcher, J., ElSohly, M., & Khan, I. (2016). Decarboxylation study of acidic cannabinoids: a novel approach using ultra-high-performance supercritical fluid chromatography/photodiode array-mass spectrometry. Cannabis Cannabinoid Research, 1(1), 262-267. https://doi.org/10.1089/can.2016.0020"}, {"Citation": "Wilkinson, J., & Williamson, E. (2007). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of Dermatological Science, 45, 87-92. https://doi.org/10.1016/j.jdermsci.2006.10.009"}], "ReferenceList": [], "Title": "REFERENCES"}], "History": [{"Year": "2022", "Month": "2", "Day": "23"}, {"Year": "2022", "Month": "1", "Day": "11"}, {"Year": "2022", "Month": "2", "Day": "23"}, {"Year": "2022", "Month": "3", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "5", "Hour": "5", "Minute": "31"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35246858", "10.1111/jvp.13048"]}}], "PubmedBookArticle": []}